Office of Sciences
The prestigious Journal of National Cancer Institute (13.76 impact factor) recently published a research paper by Drs. Jon Weidanz and Maciej Markiewski (Department of Immunotherapeutics and Biotechnology - Abilene).
The article, titled "Antitumor Activity of a Monoclonal Antibody Targeting Major Histocompatiility Complex Class I-Her2 Peptide Complexes," reports their research on a new T-csll receptor-mimicking antibody, which is specific for the complex of HLA-A2 and the HER2 peptide E75 and can overcome the primary limitation of most currently available anti-HER2 therapies, which is that they are inactive in tumors with low HER2 expression.
The manuscript was published electronically on Jan. 8, 2013. The Journal of National Cancer Institute also published an editorial that highlights the work. The editorial is titled, "HER2-Directed T-Cell Receptor-Mimicking Antibody: A "Me Too" or an Example of Novel Antitumor Aggressive Mimickry?"
The Office of Sciences at the TTUHSC School of Pharmacy congratulates these researchers for their success and hopes this will lead to breakthroughs in treatment of cancer.
Drs. Jon Weidanz (left) and Maciej Markiewski.